Table 1 Clinical information of patients.

From: A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC

Number

Gender

Age range

Pathological diagnosis

Histological grade

Treatment regimens

chemo_1

Male

66–70

ESCC

moderately differentiation

Nedaplatin+Paclitaxel

chemo_2

Male

66–70

ESCC

poorly differentiation

Cisplatin+Paclitaxel

chemo_3

Male

60–65

ESCC

moderately differentiation

Cisplatin+Paclitaxel

immuno_1

Female

71–75

ESCC

moderately differentiation

Nedaplatin+Paclitaxel+Sintilimab

immuno_2

Male

60–65

ESCC

poorly differentiation

Nedaplatin+Paclitaxel+Sintilimab

immuno_3

Male

60–65

ESCC

moderately differentiation

Nedaplatin+Paclitaxel+Sintilimab

  1. All 6 patients received neoadjuvant chemotherapy or neoadjuvant immunotherapy combined with chemotherapy. These patients had not previously undergone any other surgery or treatment. The pathological type was ESCC. Histological grade was moderate or low differentiation. The neoadjuvant chemotherapy group was treated with nedaplatin or cisplatin combined with paclitaxel. Neoadjuvant immunotherapy combined with chemotherapy was treated with nedaplatin, paclitaxel and sintilimab.
Back to article page